↓ Skip to main content

Cooling down with Entresto. Can sacubitril/valsartan combination enhance browning more than coldness?

Overview of attention for article published in Diabetology & Metabolic Syndrome, November 2022
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
3 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cooling down with Entresto. Can sacubitril/valsartan combination enhance browning more than coldness?
Published in
Diabetology & Metabolic Syndrome, November 2022
DOI 10.1186/s13098-022-00944-4
Pubmed ID
Authors

Marina Nikolic, Jovana Novakovic, Galina Ramenskaya, Vladimir Kokorekin, Nevena Jeremic, Vladimir Jakovljevic

Abstract

It is a growing importance to induce a new treatment approach to encourage weight loss but also to improve maintenance of lost weight. It has been shown that promotion of brown adipose tissue (BAT) function or acquisition of BAT characteristics in white adipose tissue (terms referred as "browning") can be protective against obesity. Amongst numerous established environmental influences on BAT activity, cold exposure is the best interested technique due to its not only effects on of BAT depots in proliferation process but also de novo differentiation of precursor cells via β-adrenergic receptor activation. A novel combination drug, sacubitril/valsartan, has been shown to be more efficient in reducing cardiovascular events and heart failure readmission compared to conventional therapy. Also, this combination of drugs increases the postprandial lipid oxidation contributing to energy expenditure, promotes lipolysis in adipocytes and reduces body weight. To date, there is no research examining potential of combined sacubitril/valsartan use to promote browning or mechanisms in the basis of this thermogenic process. Due to the pronounced effects of cold and sacubitril/valsartan treatment on function and metabolism of BAT, the primary goal of further research should focused on investigation of the synergistic effects of the sacubitril/valsartan treatment at low temperature environmental conditions.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 3 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 3 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 1 33%
Unknown 2 67%
Readers by discipline Count As %
Unspecified 1 33%
Unknown 2 67%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 November 2022.
All research outputs
#21,168,135
of 23,822,306 outputs
Outputs from Diabetology & Metabolic Syndrome
#588
of 706 outputs
Outputs of similar age
#369,581
of 461,620 outputs
Outputs of similar age from Diabetology & Metabolic Syndrome
#24
of 29 outputs
Altmetric has tracked 23,822,306 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 706 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 461,620 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.